- Atlas
- Medicine & Health
- Pharmacometrics
Pharmacometrics
Pharmacometrics is the science of building mathematical models of how drugs behave in the body and how bodies respond to them, and then using those models to make decisions about drug development and treatment.
15 frameworks, from 1930 to today · Pharmacology · Medicine & Health
- Compartmental pharmacokinetics 1930-Present
- Pharmacodynamic modeling 1960-Present
- Michaelis–Menten kinetics 1965-Present
- Noncompartmental analysis 1970-Present
- Model-Informed Precision Dosing 1975-Present
- Nonlinear mixed-effects modeling 1977-Present
- Optimal experimental design 1980-Present
- PKPD model 1980-Present
- Learn-confirm paradigm 1989-Present
- Physiologically based pharmacokinetic modelling 1990-Present
- Bayesian pharmacometrics 1995-Present
- Clinical trial simulation 1995-Present
- Model-based meta-analysis 2000-Present
- Model-informed drug development 2000-Present
- Quantitative systems pharmacology 2010-Present
Overview
Pharmacometrics is the science of building mathematical models of how drugs behave in the body and how bodies respond to them, and then using those models to make decisions about drug development and treatment1. Its practitioners are not primarily bench scientists; they are modelers who work with data from clinical trials, patient populations, and laboratory experiments to answer questions that would otherwise require enormous, expensive studies: What dose should be given to a child? How should a drug be adjusted for a patient with kidney failure2? Is a failed trial a failure of the drug or of the dose chosen? The field matters because most drugs fail in development, and many that succeed are used at doses chosen by habit rather than by quantitative reasoning. Pharmacometrics is the discipline that tries to replace habit with calculation.
The Roots: Compartmental Thinking and the Mathematics of Elimination
The earliest strand of pharmacometrics is pharmacokinetics—the study of what the body does to a drug. In the 1920s and 1930s, pharmacologists began describing drug concentrations in blood and tissues using simple mathematical models. The key idea was the compartment: a simplified "space" within the body that a drug enters and leaves at measurable rates. A one-compartment model treats the whole body as a single well-mixed volume; a two-compartment model adds a peripheral tissue compartment. These models allowed scientists to estimate clearance (how quickly the body removes a drug) and volume of distribution (how widely a drug spreads), parameters that could be compared across drugs and species.
A parallel development was the recognition that drug elimination is not always proportional to concentration. In 1913, Leonor Michaelis and Maud Menten had described enzyme kinetics in which the reaction rate saturates at high substrate concentrations. When pharmacologists applied this to drug metabolism—notably in the 1960s and 1970s with drugs like phenytoin and ethanol—they found that Michaelis–Menten kinetics explained why some drugs accumulate disproportionately when doses are increased. The mathematics was borrowed from enzymology, but the clinical implication was new: for a drug with saturable metabolism, a small dose increase can produce a large, dangerous rise in blood concentration. This insight became a standard part of dose selection.
Noncompartmental Analysis and the Rise of Clinical Pharmacokinetics
Not every pharmacokinetic question required a structural model. In the 1970s and 1980s, noncompartmental analysis (NCA) became a standard tool. NCA estimates exposure measures such as the area under the concentration–time curve (AUC) and maximum concentration (Cmax) directly from observed data using numerical integration, without assuming a compartmental structure. It is robust and widely used for regulatory submissions, but it describes rather than explains: it cannot predict what will happen at a dose not studied, or in a population not enrolled.
The limitation of NCA—and of fitting models to one patient at a time—was the problem that nonlinear mixed-effects modeling (NLME) solved. In the 1970s and 1980s, statisticians and pharmacologists developed methods to fit pharmacokinetic models simultaneously to data from many individuals, estimating both typical population parameters and the variability between patients. The approach, associated with software such as NONMEM (developed by Lewis Sheiner and Stuart Beal at the University of California, San Francisco, beginning in the late 1970s), treated each patient's parameters as a random deviation from a population mean. This made it possible to identify which patient characteristics—weight, age, kidney function, genotype—explained variability, and to quantify how much variability remained unexplained. Sheiner, a physician and engineer, was a central figure in articulating the philosophy behind this: that drug development should be a learning process, with models updated as data accumulate.
Pharmacodynamics: Modeling What the Drug Does
Pharmacokinetics describes concentration; pharmacodynamic modeling describes the relationship between concentration and effect123. Early pharmacodynamic models used simple equations—the Hill equation, borrowed from receptor theory, relates drug concentration to fractional occupancy or response. But clinical effects are often delayed relative to plasma concentration, because the drug must reach a site of action, or because the effect is mediated by a downstream cascade. In the 1980s and 1990s, modelers developed effect-compartment models and indirect-response models to capture these delays. A concrete example: the anticoagulant effect of warfarin, measured by INR, lags behind plasma warfarin concentration by hours to days; an indirect-response model that accounts for the turnover of clotting factors explains the lag and allows prediction of the time course of effect after a dose change.
The integration of pharmacokinetics and pharmacodynamics into a single PK/PD model became the core of pharmacometric reasoning: the model predicts the time course of effect, not just of concentration, and therefore can be used to simulate alternative dosing regimens.
Physiologically Based Pharmacokinetic Modeling
A different modeling tradition asked not "how many compartments?" but "what are the actual organs?" Physiologically based pharmacokinetic (PBPK) modeling represents the body as a network of anatomically defined compartments—liver, kidney, muscle, fat, brain—connected by blood flow, each with its own volume and partition coefficient. The approach has roots in the 1930s work of Torsten Teorell, who proposed a circulation-based model of drug distribution, but it matured in the 1990s and 2000s as computing power and physiological data improved. PBPK's distinctive strength is extrapolation: because its parameters have physiological meaning, it can predict drug behavior in populations not studied—children, pregnant women, patients with organ impairment—by adjusting organ sizes, blood flows, and enzyme activities. Regulatory agencies now accept PBPK analyses in lieu of some clinical studies, particularly for pediatric dosing and drug–drug interaction assessment.
Bayesian Thinking and Optimal Design
A parallel thread in pharmacometrics is Bayesian statistics—the framework in which prior knowledge is combined with new data to produce updated probability distributions for parameters4. Bayesian methods entered pharmacokinetics in the 1970s and 1980s, notably through the work of Sheiner and colleagues on Bayesian adaptive control of drug dosing: individualizing a patient's dose by combining a population model (the prior) with that patient's measured drug concentrations (the likelihood). This was applied clinically in therapeutic drug monitoring for drugs with narrow therapeutic windows, such as aminoglycosides and immunosuppressants.
Optimal design theory, developed in the statistical literature and adapted to pharmacometrics, asked a related question: given a model and a set of candidate sampling times, which times yield the most information about the parameters? This allowed trial designers to reduce the number of blood samples per patient while preserving the ability to estimate key parameters—a practical advance that made population pharmacokinetic studies feasible in settings where intensive sampling was impossible.
Model-Informed Drug Development and Meta-Analysis
By the 2000s, the pieces had come together into a framework now called model-informed drug development (MIDD). The idea is that models should inform decisions at every stage: dose selection for first-in-human trials, trial simulation to choose sample sizes and endpoints, bridging strategies to support approval in new populations, and label optimization. The U.S. Food and Drug Administration and the European Medicines Agency began formal programs to review pharmacometric analyses as part of regulatory submissions; the FDA's MIDD pilot program, launched in 2018, explicitly invited sponsors to use models to support dosing decisions.
A related development was model-based meta-analysis, which fits a single model to summary-level data from many published trials, allowing comparison of drugs and doses across studies that were never designed to be compared. This approach became influential in therapeutic areas where head-to-head trials are rare, such as diabetes and rheumatoid arthritis, by quantifying dose–response relationships across competing agents.
The Present: Simulation, Systems, and the Limits of Prediction
Contemporary pharmacometrics is dominated by simulation. A typical analysis builds a population PK/PD model, then runs thousands of virtual trials under different dosing scenarios to estimate the probability of achieving a target exposure or response. This "clinical trial simulation" approach is now standard in dose selection and is increasingly used to support labeling decisions for special populations.
The field's open questions are substantial. How much can models predict before data exist—for a new drug in a new population, or for a drug with a novel mechanism? PBPK and quantitative systems pharmacology (which adds mechanistic biological networks to the pharmacokinetic framework) push toward greater mechanistic detail, but each added parameter demands data that may not be available. The tension between parsimony and realism is unresolved. A second open question is the integration of pharmacogenomic data: models can include genotype as a covariate, but the effect sizes for most gene–drug pairs remain uncertain, and the clinical utility of genotype-guided dosing is established for only a minority of drugs. A third is the validation of models themselves: how does one know that a model's predictions are trustworthy? The field has developed diagnostic tools—visual predictive checks, bootstrap confidence intervals—but no universal standard for model credibility exists, and regulatory acceptance still depends on case-by-case review.
The through-line from the 1920s compartment to today's virtual patient is a single ambition: to make the behavior of drugs in the body calculable, and therefore predictable, before the patient is exposed.
References
- Pharmacometrics (introduction, Pharmacodynamics (PD)), Wikipedia
- Pharmacokinetics (Population pharmacokinetics, introduction), Wikipedia
- Pharmacodynamics, Wikipedia
- Bayesian statistics, Wikipedia
The frameworks of Pharmacometrics
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1930-Present
Compartmental pharmacokinetics
How does drug concentration change over time?
- 1960-Present
- 1965-Present
Michaelis–Menten kinetics
Why does elimination saturate at high concentrations?
- 1970-Present
Noncompartmental analysis
How much drug exposure occurred without a model?
- 1975-Present
- 1977-Present
Nonlinear mixed-effects modeling
How do patients differ in drug handling?
- 1980-Present
- 1980-Present
- 1989-Present
- 1990-Present
Physiologically based pharmacokinetic modelling
How does drug distribute among organs?
- 1995-Present
- 1995-Present
- 2000-Present
- 2000-Present
Model-informed drug development
How should models guide drug development?
- 2010-Present
Quantitative systems pharmacology
How does drug action unfold mechanistically?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Pharmacodynamic modeling influenced by Compartmental pharmacokinetics
Compartmental pharmacokinetic models supplied the concentration-time input that pharmacodynamic models relate to effect, as in the effect-compartment models developed by Sheiner and colleagues in the late 1960s and 1970s.
Carried by Lewis B. Sheiner.
Nonlinear mixed-effects modeling influenced by Compartmental pharmacokinetics
Nonlinear mixed-effects modeling took the compartmental pharmacokinetic model as the structural model to be fitted simultaneously to many individuals, as implemented in NONMEM by Sheiner and Beal.
Carried by Lewis B. Sheiner; Stuart Beal; NONMEM.
PKPD model grew out of Pharmacodynamic modeling
PK/PD modeling joined pharmacokinetic models to pharmacodynamic effect models (including effect-compartment and indirect-response models) into a single integrated model predicting the time course of effect.
Carried by Lewis B. Sheiner.
Clinical trial simulation influenced by Nonlinear mixed-effects modeling
Clinical trial simulation runs virtual trials from population PK/PD models estimated by nonlinear mixed-effects modeling, propagating parameter uncertainty and between-patient variability.
Model-informed drug development grew out of Learn-confirm paradigm
The learn-confirm paradigm articulated by Sheiner in 1989 framed drug development as iterative model updating, and model-informed drug development generalized this into a regulatory and industrial framework.
Carried by Lewis B. Sheiner.
Noncompartmental analysis reacted against Compartmental pharmacokinetics
Noncompartmental analysis was developed as a model-free alternative for estimating exposure (AUC, Cmax) when compartmental assumptions were unwanted or unverifiable, using numerical integration of observed concentration-time data.
Physiologically based pharmacokinetic modelling influenced by Compartmental pharmacokinetics
Physiologically based pharmacokinetic modeling replaced abstract compartments with anatomically defined organ compartments connected by blood flow, building on the compartment concept while giving parameters physiological meaning.
Optimal experimental design influenced by Nonlinear mixed-effects modeling
Optimal design theory was adapted to population pharmacokinetic models, using the Fisher information matrix to choose sampling times that best estimate mixed-effects model parameters.
PKPD model influenced by Nonlinear mixed-effects modeling
Population nonlinear mixed-effects methods were applied to joint PK/PD models, allowing estimation of pharmacodynamic parameters and their between-patient variability from sparse data.
Bayesian pharmacometrics influenced by Nonlinear mixed-effects modeling
Bayesian pharmacometrics applied Bayesian estimation to nonlinear mixed-effects population models, using MCMC and related methods to obtain posterior distributions of population parameters.
Clinical trial simulation influenced by PKPD model
Integrated PK/PD models provide the exposure-response structure that clinical trial simulation uses to predict trial outcomes under alternative dosing regimens.
Quantitative systems pharmacology influenced by PKPD model
Quantitative systems pharmacology extended the PK/PD modeling tradition from empirical effect models to mechanistic, pathway-level models of drug action and disease.
Model-informed drug development influenced by Physiologically based pharmacokinetic modelling
PBPK analyses for pediatric dosing and drug-drug interactions were accepted by regulators as part of model-informed drug development submissions, extending MIDD to extrapolation beyond studied populations.
Model-informed drug development influenced by Clinical trial simulation
Clinical trial simulation became a central tool within model-informed drug development for dose selection and trial design decisions submitted to regulators.
Quantitative systems pharmacology influenced by Pharmacodynamic modeling
Quantitative systems pharmacology inherited the concentration-response and effect-turnover concepts of pharmacodynamic modeling, embedding them in mechanistic systems of differential equations.
Clinical trial simulation influenced by Optimal experimental design
Optimal design methods were used to specify sampling schedules within simulated trials, improving the efficiency of clinical trial simulation studies.
Model-informed drug development influenced by Model-based meta-analysis
Model-based meta-analysis of published trials supplied comparative dose-response evidence used within model-informed drug development for dose and comparator selection.
Beyond the field
Where Pharmacometrics's ideas came from in other fields, and what they led to there: the strongest 12 of 90 links.
Compartmental pharmacokinetics led to Physiologically based pharmacokinetic modelling in Pharmacokinetics
Compartmental pharmacokinetics provided the rate constants, clearance concepts and parameter-estimation methods that physiologically based modelling replaced with anatomically explicit organ compartments while retaining the same mass-balance mathematics.
Compartmental pharmacokinetics influenced Population pharmacokinetics and Bayesian individualization in Clinical Pharmacology
Population pharmacokinetic estimation takes the compartmental model as its structural basis, adding random effects for between-subject and residual variability. Without compartmental pharmacokinetics there would be no model to fit to sparse population data.
Carried by Lewis B. Sheiner; NONMEM.
Pharmacodynamic modeling influenced by Pharmacokinetics in Pharmacology
Pharmacodynamic modeling links effect to concentration, and it depends on pharmacokinetic models to supply the concentration-time course; PK/PD modeling joined the two explicitly from the 1960s.
Carried by Pharmacokinetics.
Pharmacodynamic modeling influenced by Pharmacokinetics in Pharmacology
The concentration predictions of pharmacokinetics are the input to pharmacodynamic models, so the later framework was built directly on pharmacokinetic theory.
Carried by Pharmacokinetics.
Pharmacodynamic modeling influenced Model-Informed Drug Development in Translational Pharmacology
Pharmacodynamic modeling, especially the Emax and sigmoid Emax models developed by Holford and Sheiner in the late 1970s and 1980s, supplied the exposure-response machinery that model-informed drug development applies to development decisions. Sheiner's later work on learning versus confirming in drug development carried this directly into the MIDD program.
Carried by Lewis B. Sheiner; Nick Holford.
Michaelis–Menten kinetics influenced by Chemical Kinetics in Physical Chemistry
The Michaelis-Menten rate law is a result of chemical kinetics, and its transfer into pharmacokinetics carried the enzyme-kinetic formalism into drug disposition modeling.
Carried by Chemical Kinetics.
Michaelis–Menten kinetics influenced by Chemical kinetics in Chemistry
Michaelis and Menten's enzyme kinetics of 1913 is the source of the saturable rate equation that pharmacokinetics applies to capacity-limited drug metabolism.
Carried by Leonor Michaelis; Maud Menten.
Model-Informed Precision Dosing grew out of Population pharmacokinetics and Bayesian individualization in Clinical Pharmacology
Model-informed precision dosing grew directly out of population pharmacokinetics with Bayesian individualization, using prior population models and patient concentrations to compute individualized doses.
Carried by Population pharmacokinetics and Bayesian individualization.
Model-Informed Precision Dosing grew out of Population pharmacokinetics in Pharmacokinetics
Population pharmacokinetics provided the structural and variability models on which model-informed precision dosing bases its individualized dose predictions.
Carried by Population pharmacokinetics.
Nonlinear mixed-effects modeling grew out of Population pharmacokinetics and Bayesian individualization in Clinical Pharmacology
Nonlinear mixed-effects modeling was developed as the estimation engine for population pharmacokinetics with Bayesian individualization, formalizing between-subject and residual variability.
Carried by Population pharmacokinetics and Bayesian individualization.
Nonlinear mixed-effects modeling grew out of Population pharmacokinetics in Pharmacokinetics
Population pharmacokinetics required methods to estimate fixed and random effects from sparse data, and nonlinear mixed-effects modeling was created to fill that need.
Carried by Population pharmacokinetics.
Nonlinear mixed-effects modeling influenced by Non-linear least squares in Regression Analysis
Nonlinear least squares supplied the numerical optimization algorithms that nonlinear mixed-effects modeling extended to include random effects.
Carried by Non-linear least squares.

Pharmacometrics is a planet in Nousfarer
Its city has a tower for each of these 15 frameworks. Land, walk in, and climb one concept at a time.
Land on PharmacometricsRelated fields
Fields its ideas are linked to
- Pharmacokinetics 23 links
- Pharmacology 21 links
- Translational Pharmacology 11 links
- Clinical Pharmacology 10 links
- Engineering Physiology 3 links
- Pharmacodynamics 2 links
- Biostatistics 2 links
- Clinical Pharmacy 2 links
- Pharmaceutics 2 links
- Reaction Engineering 1 link
- Chemistry 1 link
- Medicinal Chemistry 1 link
More in Pharmacology
- Clinical Pharmacology
- Drug Discovery
- Pharmacodynamics
- Pharmacogenomics
- Pharmacokinetics
- Pharmacology
- Pharmacovigilance
- Receptor Theory And Signal Transduction
- Toxicology
- Translational Pharmacology
See where Pharmacometrics sits on the Map of Human Knowledge